Moderna (MRNA) is trading higher as the market reacts to a near-term catalyst: scheduled late-breaking oral presentations at ESCMID Global 2026 in Munich (April 17–21, 2026) featuring revaccination data for mRESVIA (Moderna’s RSV vaccine) and its investigational seasonal influenza vaccine, mRNA-1010. With the readouts framed as late-breaking and the timing close, investors are buying ahead of the data window, adding fuel to a rebound that has already carried the shares back into the low-$50 range in recent sessions.

Respiratory vaccines remain the core of Moderna’s near-term commercial narrative as it broadens beyond its original COVID franchise. Revaccination performance is closely watched because it can influence clinician confidence, payer positioning, and uptake in repeat-season markets where durability, safety, and consistency across seasons can matter as much as first-dose efficacy. For mRNA-1010 specifically, the company is working through U.S. regulatory friction after receiving a Refusal-to-File letter for its BLA earlier this year, which raises the bar for any dataset that could clarify the product’s path forward and improve sentiment around the flu program.

Key watch items over the coming sessions are (1) any additional details on endpoints, cohorts, and safety signals ahead of the ESCMID presentations, (2) follow-through buying tied to conference headlines between April 17 and April 21, 2026, and (3) whether investors interpret the revaccination data as supportive of broader respiratory-season commercialization. Traders will also be sensitive to volatility around event-driven positioning, given that conference catalysts can create sharp, headline-dependent moves in both directions.